Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension study
- 16 March 2012
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 27 (5) , 634-642
Abstract
Background REVEAL was a 52‐week study of adalimumab for moderate to severe psoriasis. At Week 33, adalimumab‐treated patients with sustained responses (PASI ≥75 at Weeks 16 and 33) were re‐randomized to receive adalimumab or placebo. Subsequently, they could receive adalimumab in an open‐label extension (OLE) study.Objective To compare long‐term efficacy and safety of adalimumab 40 mg every other week (eow), given as continuous treatment or with one period of interruption followed by retreatment.Methods Patients who were re‐randomized to adalimumab or placebo at REVEAL Week 33 and received ≥1 dose of OLE adalimumab were analysed as the continuous and retreatment groups, respectively, for >2 years of OLE treatment with adalimumab 40 mg eow. LOCF was used for missing efficacy data.Results At OLE Weeks 0, 12 and 24, PASI 75 response rates were 84%, 84%, 86% with continuous treatment (N = 233) vs. 45%, 71%, 79% with retreatment (N = 227). Thereafter, efficacies were slightly greater for continuous treatment but similar between groups, with PASI 75 response rates at OLE Week 108 of 75% vs. 73% respectively. Retreatment was most effective for patients with ≥PASI 50 responses when retreatment was initiated. Adverse event rates for retreatment were equal to or lower than those for continuous treatment.Conclusions In psoriasis patients with sustained PASI 75 responses to adalimumab, long‐term efficacy of retreatment after a ≤19‐week interruption was similar to efficacy achieved with >3 years continuous treatment. Adalimumab retreatment provided the best results when initiated before responses had declined below PASI 50.Keywords
This publication has 23 references indexed in Scilit:
- Psoriasis: is the impairment to a patient’s life cumulative?Journal of the European Academy of Dermatology and Venereology, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasisBritish Journal of Dermatology, 2010
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled studyThe Journal of Dermatology, 2010
- Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritisDermatologic Therapy, 2009
- Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque PsoriasisDermatology, 2008
- Psoriasis comorbiditiesJournal of Dermatological Treatment, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisJournal of the American Academy of Dermatology, 2007
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006